sb 203580 has been researched along with durapatite in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (durapatite) | Trials (durapatite) | Recent Studies (post-2010) (durapatite) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 17,101 | 522 | 7,832 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanaya, S; Nemoto, E; Shimauchi, H; Suto, M; Suzuki, R; Tsuchiya, M | 1 |
1 other study(ies) available for sb 203580 and durapatite
| Article | Year |
|---|---|
Nanohydroxyapatite increases BMP-2 expression via a p38 MAP kinase dependent pathway in periodontal ligament cells.
Topics: Adult; Blotting, Western; Bone Morphogenetic Protein 2; Calcium; Cell Culture Techniques; Cell Nucleus; Cells, Cultured; Dose-Response Relationship, Drug; Durapatite; Enzyme Inhibitors; Fluorescent Dyes; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Nanoparticles; p38 Mitogen-Activated Protein Kinases; Periodontal Ligament; Phosphates; Phosphorylation; Pyridines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Young Adult | 2013 |